327 related articles for article (PubMed ID: 27306852)
1. Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin.
Rosario PW; Mourão GF; Calsolari MR
Nucl Med Commun; 2016 Oct; 37(10):1024-9. PubMed ID: 27306852
[TBL] [Abstract][Full Text] [Related]
2. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.
Mourão GF; Rosario PW; Calsolari MR
Endocr Relat Cancer; 2016 Jan; 23(1):47-52. PubMed ID: 26503963
[TBL] [Abstract][Full Text] [Related]
3. Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in patients with papillary thyroid cancer of intermediate risk 'with higher risk features'.
Rosario PW; Mourão GF; Calsolari MR
Clin Endocrinol (Oxf); 2016 Sep; 85(3):453-8. PubMed ID: 26801644
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of adjuvant therapy with 3.7 GBq radioactive iodine in intermediate-risk patients with 'higher risk features' and predictive value of postoperative nonstimulated thyroglobulin.
Rosario PW; Mourão GF; Calsolari MR
Nucl Med Commun; 2016 Nov; 37(11):1148-53. PubMed ID: 27341413
[TBL] [Abstract][Full Text] [Related]
5. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
6. A low postoperative nonstimulated serum thyroglobulin level excludes the presence of persistent disease in low-risk papillary thyroid cancer patients: implication for radioiodine indication.
Rosario PW; Mourão GF; Siman TL; Calsolari MR
Clin Endocrinol (Oxf); 2015 Dec; 83(6):957-61. PubMed ID: 25393656
[TBL] [Abstract][Full Text] [Related]
7. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Prates BS; Silva LC; Calsolari MR
Thyroid; 2012 Nov; 22(11):1140-3. PubMed ID: 23050786
[TBL] [Abstract][Full Text] [Related]
8. Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.
Rosario PW; Mourão G; Calsolari MR
J Endocrinol Invest; 2019 Jun; 42(6):687-692. PubMed ID: 30353424
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation?
Wong H; Wong KP; Yau T; Tang V; Leung R; Chiu J; Lang BH
Ann Surg Oncol; 2012 Oct; 19(11):3479-85. PubMed ID: 22576067
[TBL] [Abstract][Full Text] [Related]
10. Day 3 thyroglobulin ≤ 1 ng/ml after recombinant human TSH just prior to radioactive iodine is predictive of low risk for persistent/recurrent disease in patients with papillary thyroid carcinoma.
Rosario PW; Siman TL; Calsolari MR
Endocrine; 2015 May; 49(1):170-4. PubMed ID: 25209895
[TBL] [Abstract][Full Text] [Related]
11. Can the follow-up of patients with papillary thyroid carcinoma of low and intermediate risk and excellent response to initial therapy be simplified using second-generation thyroglobulin assays?
Rosario PW; Mourão GF; Calsolari MR
Clin Endocrinol (Oxf); 2016 Oct; 85(4):596-601. PubMed ID: 26940991
[TBL] [Abstract][Full Text] [Related]
12. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
[TBL] [Abstract][Full Text] [Related]
13. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
14. Can patients with papillary thyroid carcinoma and low postoperative thyroglobulin in the presence of clinically apparent lymph node metastases (cN1) be spared from radioiodine?
Rosario PW; Mourão GF; Calsolari MR
Endocrine; 2020 Dec; 70(3):552-557. PubMed ID: 32653994
[TBL] [Abstract][Full Text] [Related]
15. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence.
Rosario PW; Xavier AC; Calsolari MR
Thyroid; 2011 Jan; 21(1):49-53. PubMed ID: 20954820
[TBL] [Abstract][Full Text] [Related]
16. Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis.
Furtado Mde S; Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2015 Aug; 59(4):285-91. PubMed ID: 26331314
[TBL] [Abstract][Full Text] [Related]
17. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.
Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM
Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913
[TBL] [Abstract][Full Text] [Related]
18. Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies.
Ramos da Silva F; Rosario PW; Mourão GF
Clin Endocrinol (Oxf); 2022 Jan; 96(1):82-88. PubMed ID: 34323308
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b).
Rosario PW; Mourão GF; Calsolari MR
Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001
[TBL] [Abstract][Full Text] [Related]
20. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
